CA3087354C — Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
Assigned to Array Biopharma Inc · Expires 2023-01-03 · 3y expired
What this patent protects
ABSTRACT Provided herein are compounds of the Formula I: NH2 Ri N LI RY and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with…
USPTO Abstract
ABSTRACT Provided herein are compounds of the Formula I: NH2 Ri N LI RY and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. 1 Date recue / Date received 2021-12-16
Drugs covered by this patent
- Retevmo (SELPERCATINIB) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.